PremiumThe FlyLargest borrow rate increases among liquid names Largest borrow rate increases among liquid names Optimistic Buy Rating for Anavex Life Sciences Amid Anticipated EMA Feedback and Strategic Preparations PremiumThe FlyAnavex reports Q2 EPS (13c) vs. (13c) last year Anavex sees cash runway of four years Largest borrow rate increases among liquid names PremiumThe FlyLargest borrow rate increases among liquid names Promising Potential of Anavex Life Sciences’ Blarcamesine in Alzheimer’s Treatment Reinforces Buy Rating Anavex announces results from Phase IIb/III open-label extension trial 
